- Home
- UBXG vs BCAB Comparison
UBXG vs BCAB Comparison
Compare UBXG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBXG
- BCAB
- Stock Information
- Founded
- UBXG 2018
- BCAB 2007
- Country
- UBXG China
- BCAB United States
- Employees
- UBXG N/A
- BCAB N/A
- Industry
- UBXG
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- UBXG
- BCAB Health Care
- Exchange
- UBXG Nasdaq
- BCAB Nasdaq
- Market Cap
- UBXG 38.2M
- BCAB 40.5M
- IPO Year
- UBXG 2024
- BCAB 2020
- Fundamental
- Price
- UBXG $2.12
- BCAB $0.70
- Analyst Decision
- UBXG
- BCAB Hold
- Analyst Count
- UBXG 0
- BCAB 3
- Target Price
- UBXG N/A
- BCAB $1.00
- AVG Volume (30 Days)
- UBXG 88.8K
- BCAB 1.5M
- Earning Date
- UBXG 01-01-0001
- BCAB 11-05-2025
- Dividend Yield
- UBXG N/A
- BCAB N/A
- EPS Growth
- UBXG N/A
- BCAB N/A
- EPS
- UBXG N/A
- BCAB N/A
- Revenue
- UBXG $29,674,534.00
- BCAB $11,000,000.00
- Revenue This Year
- UBXG N/A
- BCAB N/A
- Revenue Next Year
- UBXG N/A
- BCAB N/A
- P/E Ratio
- UBXG N/A
- BCAB N/A
- Revenue Growth
- UBXG N/A
- BCAB N/A
- 52 Week Low
- UBXG $1.62
- BCAB $0.24
- 52 Week High
- UBXG $6.04
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- UBXG 49.92
- BCAB 48.83
- Support Level
- UBXG $2.04
- BCAB $0.67
- Resistance Level
- UBXG $2.30
- BCAB $0.76
- Average True Range (ATR)
- UBXG 0.21
- BCAB 0.10
- MACD
- UBXG 0.03
- BCAB -0.02
- Stochastic Oscillator
- UBXG 53.42
- BCAB 30.23
About UBXG U-BX Technology Ltd. Ordinary Shares
U-BX Technology Ltd is focused on providing value-added services using artificial intelligence-driven technology to businesses within the insurance industry, including insurance carriers and brokers. It helps institutional clients obtain visibility on various social media platforms and generate revenue based on consumers' clicks, views, or its clients' promotion time through those channels. The company derives a majority of its revenue by providing digital promotion services to its clients and also engages in providing risk assessment services, and value-added bundled benefits. It has developed an algorithm named Magic Mirror, to calculate payout risks for insurance carriers to underwrite auto insurance coverage. Geographically, all of the company's revenue is derived from Mainland China.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.